Journal
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
Volume 6, Issue 1, Pages 158-162Publisher
SPRINGER
DOI: 10.1007/s11481-010-9226-7
Keywords
multiple sclerosis; interferon-beta; excipients; disaccharides/chemistry
Categories
Funding
- Aegis Therapeutics, LLC
- Nerveda, Inc.
- The Johns Hopkins University
Ask authors/readers for more resources
The development of neutralizing antibodies to the protein drug interferon-beta is a significant impediment to its use in the treatment of multiple sclerosis. Neutralizing antibodies to interferon-beta arise from aggregation of the peptide during manufacturing and storage. We tested the ability of dodecylmaltoside, a nontoxic alkylsaccharide surfactant, to reduce aggregation of interferon-beta in vitro and to reduce its immunogenicity in vivo. Interferon-beta, in solution with and without dodecylmaltoside, was periodically evaluated for aggregation by light scatter for 1 month. Interferon-beta, with and without dodecylmaltoside, was given 3 days/week for 1 month to mice; the sera of these mice were analyzed for anti-interferon-beta antibodies by ELISA. Dodecylmaltoside reduces the aggregation of interferon-beta in vitro and its immunogenicity in vivo. Our positive findings warrant additional tests of dodecylmaltoside as a therapeutic adjuvant in rodent models of multiple sclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available